Laman Utama207940 • KRX
Samsung Biologics Co Ltd
â‚©1,012,000.00
14 Jan, 2:11:11 PG GMT+9 · KRW · KRX · Penafian
Saham
Tutup sebelumnya
â‚©1,000,000.00
Julat hari
â‚©1,005,000.00 - â‚©1,044,000.00
Julat tahun
â‚©721,000.00 - â‚©1,113,000.00
Permodalan pasaran
72.03T KRW
Bilangan Purata
71.47K
Nisbah P/E
68.43
Hasil dividen
-
Markah Perubahan Iklim CDP
A-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(KRW)Sep 2024Perubahan T/T
Hasil
1.19T14.81%
Perbelanjaan pengendalian
202.29B11.50%
Pendapatan bersih
264.47B10.03%
Margin untung bersih
22.28-4.17%
Pendapatan bagi setiap syer
3.72K10.07%
EBITDA
495.40B8.39%
Kadar cukai berkesan
9.12%—
Jumlah aset
Jumlah liabiliti
(KRW)Sep 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
988.11B-45.63%
Jumlah aset
16.03T0.87%
Jumlah liabiliti
5.43T-14.30%
Jumlah ekuiti
10.59T—
Syer tertunggak
71.17J—
Harga kepada buku
6.72—
Pulangan pada aset
5.23%—
Pulangan pada modal
7.18%—
Perubahan bersih dalam tunai
(KRW)Sep 2024Perubahan T/T
Pendapatan bersih
264.47B10.03%
Tunai daripada operasi
740.39B154.07%
Tunai daripada pelaburan
-437.12B-17.41%
Tunai daripada pembiayaan
-713.37B-297.72%
Perubahan bersih dalam tunai
-433.28B-69.49%
Aliran tunai bebas
-12.12B-237.42%
Perihal
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines. The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
Diasaskan
2011
Pekerja
4,744
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama